

Human Papillomavirus Vaccine

Pathophysiology	Certain types of human papillomavirus can cause squamous cell cervical cancer, cervical adenocarcinoma, and genital warts.														
Vaccine Description	9vHPV(Gardasil™) HPV types 6,11,16,18, 31, 33, 45, 52 and 58														
Dose & Route	0.5 mL given intramuscularly														
Administration Schedule & Minimum Intervals If the HPV vaccine schedule is interrupted, the vaccine series does not need to be restarted.	<p>2 Dose Schedule (Persons initiating the 1st dose prior to their 15th birthday)</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Dose</th> <th style="text-align: right;">Minimum Interval</th> </tr> </thead> <tbody> <tr> <td>Dose 1</td> <td style="text-align: right;">0</td> </tr> <tr> <td>Dose 2</td> <td style="text-align: right;">6-12 months (5 months minimal interval from dose-1)</td> </tr> </tbody> </table> <p>3 Dose Schedule (Persons initiating vaccine after their 15th birthday or immunocompromised persons)</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Dose</th> <th style="text-align: right;">Minimum Interval</th> </tr> </thead> <tbody> <tr> <td>Dose 1</td> <td style="text-align: right;">0</td> </tr> <tr> <td>Dose 2</td> <td style="text-align: right;">2 months after dose-1 (4 weeks)</td> </tr> <tr> <td>Dose 3</td> <td style="text-align: right;">6 months after dose-1 (12 weeks minimal interval from dose-2 and 24 weeks from dose-1)</td> </tr> </tbody> </table> <ul style="list-style-type: none"> • Also recommended for males and females ages 13 through 26 who did not receive the vaccine previously • May be given at the same visit with other vaccines • Should be given to persons with a previous history of HPV infection • recommended for gay and bisexual men • Recommended for men and women with compromised immune systems (including people living with HIV/AIDS) through age 26, if they did not get fully vaccinated when they were younger. • Can be given based on shared clinical decision making for males and females ages 27 through 45 	Dose	Minimum Interval	Dose 1	0	Dose 2	6-12 months (5 months minimal interval from dose-1)	Dose	Minimum Interval	Dose 1	0	Dose 2	2 months after dose-1 (4 weeks)	Dose 3	6 months after dose-1 (12 weeks minimal interval from dose-2 and 24 weeks from dose-1)
Dose	Minimum Interval														
Dose 1	0														
Dose 2	6-12 months (5 months minimal interval from dose-1)														
Dose	Minimum Interval														
Dose 1	0														
Dose 2	2 months after dose-1 (4 weeks)														
Dose 3	6 months after dose-1 (12 weeks minimal interval from dose-2 and 24 weeks from dose-1)														
Minimum Age	Minimum age for all HPV vaccine is 9 years.														
Contraindications	Anaphylactic reaction to any vaccine component or to previous dose of vaccine														



Precautions	<ul style="list-style-type: none">• Not recommended for use in pregnant women• Not intended for treatment of active genital warts or cervical cancer• Moderate or severe acute illness with fever
Special Considerations Remember there is a VIS just for HPV9.	Vaccination <u>in no way</u> should replace: <ul style="list-style-type: none">• routine, periodic cervical cancerscreening• protective sexual behaviors• Syncope can occur after vaccination, most commonly among adolescents and young adults. To avoid serious injury related to syncope episode, observation for 15 minutes after administration is recommended.• HPV vaccines are most effective for both males and females when given before first exposure to HPV through sexual contact.• HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the 3-dose series should be delayed until completion of pregnancy.